First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial

Nature·Mar 16

This story is reported by Nature. Read what other outlets are saying below, then open the original report for full details.